|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/11796
Full metadata record
DC Field | Value | Language |
dc.contributor.author | Galașanu, Anghelina | |
dc.date.accessioned | 2020-09-29T14:43:11Z | |
dc.date.available | 2020-09-29T14:43:11Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | GALAȘANU, Anghelina. Paracetamol - benefits and damages. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 282-283. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11796 | |
dc.description | Departament of Pharmacology and Clinical Pharmacology, Nicolae Testemitanu State
University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 | en_US |
dc.description.abstract | Introduction. Paracetamol and the combined drugs, which belong to the OTC list that are
released without a prescription, are most commonly used in the symptomatic treatment or selftreatment
of acute respiratory infections. The diversity of trade names often misleads patients
who resort to their administration without consulting a doctor. For these reasons, there is an
increase in the incidence of acute intoxication and fatal adverse reactions (fulminant hepatic
necrosis, etc.). Aim of the study. The aim of the study consisted in analyzing the presence on the
pharmaceutical market of mono- and combined drugs containing paracetamol and estimating
possible risk of side effects in self-treatment with them.
Materials and methods. Based on the study of the State Drug Nomenclature, were selected
drugs containing paracetamol with analysis of single dose and combination diversity.
Results. In the Republic of Moldova there are 95 mono- or combined drugs containing
paracetamol (acetaminophen), including producers from: Moldova - 22, Romania - 20, Ukraine
13, Belarus - 12, Turcia - 5, Russia - 5, Slovenia - 6, Georgia - 4, India - 4, Bosnia and
Herzegovina - 2, United Kingdom -1, Germany - 1. The presence of single-dose mono drugs
containing paracetamol of 50-250 mg for children and 500-600 mg for adults was found. There
is a wide range of combined drugs including: paracetamol + decongestant adrenomimetics
(phenylephrine, pseudoephedrine), paracetamol + H1-antihistamines (pheniramine, chlorophenamine), paracetamol + adrenomimetics + H1-anehistamine +, paracetamol +
opacimetamine ), paracetamol + H1-anihistamines + opioid analgesics (codeine,
promethazine), paracetamol + non-inflammatory anti-inflammatory drugs (propifenazone),
paracetamol + antitussive opioid analgesics (codeine, dextromethorphan), which in some cases
may have caffeine and / or ascorbic acid added. In accordance with the recommendations of
the European Medicines Association the dose of paracetamol in adults for 24 hours is 3.2 g,
and in the case of people with pre-existing hepatitis and those who suffer from alcohol abuse,
of 2g / 24 hours. The presence of the H1-antihistamine component can result in diminished
attention with tragic consequences for drivers, people who do machinery work, as well as the
development of dry mucous membranes, including the tracheo-bronchial mucosa, which can
enhance the dry cough and decrease the bronchial drainage creating the feeling of
ineffectiveness of said drugs. The effect of improved breathing, through the decongestant
adrenomimetics, is of short duration (1-2 hours), especially in the first 24-48 hours, which
stimulates the more frequent use of drugs with systemic effects, including increased blood
pressure, palpitations, tremor.
Conclusions. The number and variety of drug combinations of paracetamol impose caution for
their use, in order to avoid overdose and the possibility of developing hepatotoxicity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | paracetamol | en_US |
dc.subject | hepatotoxicity | en_US |
dc.title | Paracetamol - benefits and damages | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|